Division of Translational and Experimental Oncology, Department of Medicine III, Johannes Gutenberg University, Mainz, Germany. Translational Oncology at the University Medical Center, Johannes Gutenberg University, Mainz gGmbH, Germany.
Division of Translational and Experimental Oncology, Department of Medicine III, Johannes Gutenberg University, Mainz, Germany.
Cancer Immunol Res. 2014 Dec;2(12):1230-44. doi: 10.1158/2326-6066.CIR-14-0108. Epub 2014 Sep 22.
The determination of the epitope specificity of disease-associated T-cell responses is relevant for the development of biomarkers and targeted immunotherapies against cancer, autoimmune, and infectious diseases. The lack of known T-cell epitopes and corresponding T-cell receptors (TCR) for novel antigens hinders the efficient development and monitoring of new therapies. We developed an integrated approach for the systematic retrieval and functional characterization of TCRs from single antigen-reactive T cells that includes the identification of epitope specificity. This is accomplished through the rapid cloning of full-length TCR-α and TCR-β chains directly from single antigen-specific CD8(+) or CD4(+) T lymphocytes. The functional validation of cloned TCRs is conducted using in vitro-transcribed RNA transfer for expression of TCRs in T cells and HLA molecules in antigen-presenting cells. This method avoids the work and bias associated with repetitive cycles of in vitro T-cell stimulation, and enables fast characterization of antigen-specific T-cell responses. We applied this strategy to viral and tumor-associated antigens (TAA), resulting in the retrieval of 56 unique functional antigen-specific TCRs from human CD8(+) and CD4(+) T cells (13 specific for CMV-pp65, 16 specific for the well-known TAA NY-ESO-1, and 27 for the novel TAA TPTE), which are directed against 39 different epitopes. The proof-of-concept studies with TAAs NY-ESO-1 and TPTE revealed multiple novel TCR specificities. Our approach enables the rational development of immunotherapy strategies by providing antigen-specific TCRs and immunogenic epitopes.
鉴定与疾病相关的 T 细胞反应的表位特异性对于开发针对癌症、自身免疫和传染病的生物标志物和靶向免疫疗法至关重要。新型抗原缺乏已知的 T 细胞表位和相应的 T 细胞受体(TCR),这阻碍了新疗法的有效开发和监测。我们开发了一种从单个抗原反应性 T 细胞中系统地检索和功能表征 TCR 的综合方法,包括鉴定表位特异性。这是通过直接从单个抗原特异性 CD8(+)或 CD4(+)T 淋巴细胞中快速克隆全长 TCR-α和 TCR-β链来实现的。通过在体外转录 RNA 转移来表达 TCR 在 T 细胞中和 HLA 分子在抗原呈递细胞中,对克隆的 TCR 进行功能验证。这种方法避免了与体外 T 细胞刺激的重复循环相关的工作和偏见,并能够快速表征抗原特异性 T 细胞反应。我们将这种策略应用于病毒和肿瘤相关抗原(TAA),从人类 CD8(+)和 CD4(+)T 细胞中检索到 56 个独特的功能性抗原特异性 TCR(13 个针对 CMV-pp65,16 个针对众所周知的 TAA NY-ESO-1,27 个针对新的 TAA TPTE),这些 TCR 针对 39 个不同的表位。用 TAA NY-ESO-1 和 TPTE 进行的概念验证研究揭示了多个新的 TCR 特异性。我们的方法通过提供抗原特异性 TCR 和免疫原性表位,为免疫疗法策略的合理发展提供了支持。